Preclinical assessment of ulixertinib, a novel ERK1/2 inhibitor. ADMET and DMPK, [S. l.], v. 5, n. 4, p. 212–223, 2017. DOI: 10.5599/admet.5.4.437. Disponível em: https://pub.iapchem.org/ojs/index.php/admet/article/view/437. Acesso em: 2 jun. 2026.